• 1
    Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 58692.
  • 2
    Van Gorp ECM, Suharti C, Ten Cate H, Dolmans WMV, Van der Meer JWM, Ten Cate JW, Brandjes DPM. Infectious diseases and coagulation disorders. J Infect Dis 1999; 180: 17686.
  • 3
    Levi M, De Jonge E, Van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 2003; 16: 437.
  • 4
    Dempfle CE. Coagulopathy of sepsis. Thromb Haemost 2004; 91: 21324.
  • 5
    Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Scientific and standardization committee communications. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 132730.
  • 6
    Hardaway RM, Williams CH, Vasquez Y. Disseminated intravascular coagulation in sepsis. Semin Thromb Hemost 2001; 27: 57783.
  • 7
    Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin, protein C, and protein S deficiencies. Chest 1992; 101: 81623.
  • 8
    Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996; 75: 2248.
  • 9
    Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin in shock and DIC: a randomized study. Thromb Res 1985; 39: 819.
  • 10
    Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104: 8828.
  • 11
    Baudo F, Caimi TM, De Cataldo F, Ravizza A, Arlati S, Casella G, Cargo D, Palareti G, Legnani C, Ridolfi L, Rossi R, DÁngelo A, Crippa L, Giudici D, Gallioli G, Wolfler A, Calori G. Antithrombin (AT) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998; 24: 33642.
  • 12
    Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias F, Fourrier F, Heinrichs H, Delvos U. Antithrombin in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin in severe sepsis. Intensive Care Med 1998; 24: 66372.
  • 13
    Bakhtiari K, Meijers JCM, De Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004; 32: 241621.
  • 14
    Toh CH, Downey C. Performance and prognostic importance of a new clinical and laboratory scoring system for identifying non-overt disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2005; 16: 6974.
  • 15
    Dhainaut J-F, Yan SB, Joyce DE, Pettilä V, Basson B, Brandt JT, Sundin DP, Levi M. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004; 2: 192433.
  • 16
    Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparin sulfate. Crit Care Med 2002; 30 (Suppl.): S32531.
  • 17
    Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin activity during severe sepsis and septic shock in neutropenic patients. Blood 1996; 88: 8816.
  • 18
    Okabayashi K, Wada H, Ohta S, Shiku H, Nobori T, Maruyama K. Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. Am J Hematol 2004; 76: 2259.
  • 19
    Dhainaut J-F, Shorr AF, Macias WL, Kollef MJ, Levi M, Reinhart K, Nelson DR. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 2005; 33: 3418.
  • 20
    Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, Knaub S, Keinecke H, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM for the KyberSept Trial Study Group. High-dose antithrombin in severe sepsis. JAMA 2001; 286: 186978.
  • 21
    Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Kaneider NC, Dunzendorfer S, Wiedermann CJ, Romisch J, Schildberg FW, Menger MD. Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 2002; 88: 24252.
  • 22
    Kleinbaum DG, Kupper LL, Morgenstern H. In: Epidemiologic Research: Principles and Quantitative Methods, Chapter 15. Belmont, CA: Wadsworth, Inc., 1982.
  • 23
    Le Gall J-R, Lemeshow S, Leleu G, Klar J, Huillard J, Rué M, Teres D, Artigas A. Customized probability models for early savere sepsis in adult intensive care units. JAMA 1995; 273: 64450.
  • 24
    Corrigan JJ, Jordan CM. Heparin therapy in septicaemia with disseminated intravascular coagulation. N Engl J Med 1970; 283: 77882.
  • 25
    Corrigan JJ. Heparin therapy in bacterial septicaemia. J Pediatr 1977; 91: 695700.
  • 26
    Straub PW. A case against heparin therapy of intravascular coagulation. Throm Diath Haemorrh 1975; 33: 10712.
  • 27
    Schipper HG, Kahle LH, Jenkins CSP, Ten Care JW, Antithrombin transfusion in disseminated intravascular coagulation. Lancet 1978; II: 8546.
  • 28
    Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M. Antithrombin supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock 1997; 8: 32834.
  • 29
    Siegal T, Seligsohn U, Aghai E, Modan M. Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases. Thromb Haemost 1978; 39: 12233.